Biosimilars

As a wave of blockbuster biologics face loss of exclusivity, some hope that there may be a “second phase” of biosimilar adoption.

Cardinal Health 2026 Biosimilars Report shows biosimilars’ savings surge, but predictable reimbursement drives physician adoption amid FDA streamlining.

To gain approvals, biosimilar manufacturers could do faster, less expensive analytical studies of their products' composition.

The biosimilar market experienced 16 new approvals by early December 2025, marking significant expansion and introducing previously unavailable biosimilar drug classes to patients.

A new Tufts study found that Medicare price negotiations on biologics with imminent biosimilars could lead to near-term savings, but greater savings are likely from biosimilar competition.

A budget model analysis finds that biosimilars for Prolia and Xgeva could provide cost savings for health plans.

The findings in a new study published in Health Affairs suggest that Semglee’s interchangeability status may have partially increased adoption by supporting improved formulary coverage.

Sandoz’s Tyruko (natalizumab), the only FDA approved natalizumab biosimilar for adults with relapsing multiple sclerosis and Crohn’s disease, is now available by prescription in the United States under a restricted-distribution program because of the drug’s risk of progressive multifocal leukoencephalopathy.

The FDA has approved Poherdy as the first interchangeable biosimilar to Perjeta, expanding treatment options for adults with HER2-positive breast cancer across both early-stage and metastatic settings.

Increased adoption of biosimilars requires regulatory changes, educational efforts, and PBM reimbursement policies that enable fair competition, argues Dr. Benjamin Rome in a new paper.

Biosimilars enhance arthritis treatment access, with rising adoption among women and long-term patients, revealing key prescribing patterns in Turkey.

Vascular endothelial growth factor (VEGF) inhibitor, Eydenzelt (aflibercept-boav), is now approved to treat retinal disease marked by excessive blood vessel growth in adults.

A recent study finds that despite biosimilar use rising to 60% to 86% for three cancer drugs, predicted savings don’t match those that would be achieved from a site-neutral reimbursement strategy.

Amneal submits a BLA for a new Xolair biosimilar, promising affordable treatment options for asthma and allergies, enhancing patient access and competition.

The FDA's groundbreaking decision to waive clinical efficacy studies for a monoclonal antibody biosimilar revolutionizes drug approval, reducing costs and enhancing patient access.

Bildyos and Bilprevda have the same indications as the reference products Prolia and Xgeva and are expected to be available later this year.

The biosimilar will be available to any licensed specialty pharmacy in the United States at a 95% discount from Stelara, starting January 1, 2026.

Prefilled syringes of Imuldosa now have the lowest wholesaler acquisition cost among all branded ustekinumab biosimilars, according to a news release.

Specialty drug spending rose 9.6% in 2024, but Humira biosimilar adoption is helping to slow cost increases.

Originally approved earlier this year for multiple inflammatory conditions, including rheumatoid arthritis, giant cell arteritis, juvenile idiopathic arthritis and COVID-19-related inflammation, Avtozma now aligns fully with the FDA-approved indications of its biosimilar, Actemra.

This biosimilars market report focuses on rising market complexity and recent activity, including two new approvals and four launches in Q2.

Since its approval in 2002, Humira has become the world’s top-selling drug—largely due to long-standing market exclusivity and rising prices in the U.S.

Wyost and Jubbonti are interchangeable with Xgeva/Prolia and are approved for all of the same indications in bone cancer and osteoporosis.

Respondents see the glucagon-like peptide 1 (GLP-1) drugs as a major advance. They also have concerns about whether insurers can afford to cover them and about wasteful prescriptions.